Updating results

1056 results

Sort: Relevance | Date

Structural neuroimaging in first-episode psychosis (TA136)

Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis

Technology appraisal guidance Published February 2008

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Prucalopride for the treatment of chronic constipation in women (TA211)

Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women

Technology appraisal guidance Published December 2010

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years

Technology appraisal guidance Published January 2011

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance Published March 2011

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes

Technology appraisal guidance Published October 2011

Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (TA20)

Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)

Technology appraisal guidance Published January 2001

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

Technology appraisal guidance Published November 2010

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2008 Last updated February 2018

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors

Technology appraisal guidance Published January 2009

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Technology appraisal guidance Published March 2009

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer

Technology appraisal guidance Published December 2010

Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence

Technology appraisal guidance Published October 2010

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)

Technology appraisal guidance Published November 2010

Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2010

Mifamurtide for the treatment of osteosarcoma (TA235)

Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)

Technology appraisal guidance Published October 2011

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

Technology appraisal guidance Published February 2011

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)

Technology appraisal guidance Published April 2012

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Golimumab for the treatment of psoriatic arthritis (TA220)

Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis

Technology appraisal guidance Published April 2011

Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

Evidence-based recommendations on Pharmalgen (ALK-Abelló) for treating bee and wasp venom allergy

Technology appraisal guidance Published February 2012

Tocilizumab for the treatment of rheumatoid arthritis (TA247)

Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis

Technology appraisal guidance Published February 2012

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

Evidence-based recommendations on endovascular stent–grafts for the treatment of abdominal aortic aneurysms

Technology appraisal guidance Published February 2009

Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

Evidence-based recommendations on tenofovir disoproxil (Viread) for the treatment of chronic hepatitis B (HBV)

Technology appraisal guidance Published July 2009

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

Evidence-based recommendations on topotecan (Hycamtin) for treating recurrent stage IVB (stage 4B) cervical cancer (cancer of the cervix)

Technology appraisal guidance Published October 2009

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2010

Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)

NICE is unable to make a recommendation about the use in the NHS of bendamustine for treating indolent (low grade) non-Hodgkin's lymphoma that is refractory

Technology appraisal guidance Published October 2010

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

Technology appraisal guidance Published December 2010

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults

Technology appraisal guidance Published July 2006

Laparoscopic surgery for colorectal cancer (TA105)

Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer

Technology appraisal guidance Published August 2006

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

Technology appraisal guidance Published June 2006

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published June 2012

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy

Technology appraisal guidance Published March 2015

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Technology appraisal guidance Published June 2013 Last updated November 2016

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with

Technology appraisal guidance Published May 2013

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015